

MAY - 7 2004

510(k) Summary - Revised

K040454

Date

April 28, 2004

Submitter

Scient'x

Batiment Calypso Parc Ariane 3

78284 Guyancourt

FRANCE

Contact person

J.D. Webb

1001 Oakwood Blvd

Round Rock, TX 78681

512-388-0199

Common name

Bone void filler

Classification name

Filler, calcium sulfate, preformed pellets

Equivalent Device

Biofill is equivalent in material, indications and use as BIOSORB (K021963) (Sciences et Bio Materiaux, Lourdes, France) and Vitoss™ Scaffold (K994337) (Orthovita, Inc. (Malvern PA).

Device Description

Biofill Bone Void Filler is a tricalcium phosphate bone void filler.

It is supplied in the form of parallelepiped granules measuring 1mm-4mm on each side. It is marketed in quantities of 5cc, 10cc and 15cc dosages.

The Biofill structure is made up of interconnected macropores occupying 60-80% of the volume of the granule. Pore size is 200-700µm with an average of 400µm. Microporosity is also present with pore size <5µm.

Intended Use

Biofill Bone Void Filler is intended for use only as bone void filler for voids or gaps that are not intrinsic to the stability of the bony structure. Biofill Bone Void Filler is indicated for use in the treatment of surgically created osseous defects or osseous defects created from traumatic injury to bone. Biofill Bone Void Filler should not be used to treat large defects that in the surgeon's opinion would fail to heal spontaneously.

Biofill Bone Void Filler is intended to be gently packed into voids or gaps in the skeletal system (i.e. extremities, spine, and pelvis). Following placement in the bony voids or gap, the calcium phosphate scaffold resorbs and is replaced with bone during the healing process

Summary Nonclinical Tests

The material described in this submission complies with ASTM F1088-87, "Standard specification for beta tricalcium phosphate for surgical implantation".



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY - 7 2004

Scient'x  
C/o J. D. Webb  
The Orthomedix Group, Inc.  
1001 Oakwood Boulevard  
Round Rock, Texas 78681

Re: K040454  
Trade/Device Name: Biofill Bone Void Filler  
Regulation Number: 21 CFR 888.3045  
Regulation Name: Resorbable calcium salt bone void filler  
Regulatory Class: II  
Product Code: MQV  
Dated: February 19, 2004  
Received: February 24, 2004

Dear Mr. Webb:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten", is written over the printed name.

Celia M. Witten, PhD, MD  
Director

Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K040454

Device Name: Biofill Bone Void Filler

### Indications for Use:

Biofill is intended for use only as bone void filler for voids or gaps that are not intrinsic to the stability of the bony structure. Biofill is indicated for use in the treatment of surgically created osseous defects or osseous defects created from traumatic injury to bone. Biofill should not be used to treat large defects that in the surgeon's opinion would fail to heal spontaneously.

Biofill is intended to be gently packed into voids or gaps in the skeletal system (i.e. extremities, spine, and pelvis). Following placement in the bony voids or gap, the calcium phosphate scaffold resorbs and is replaced with bone during the healing process.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of General, Restorative,  
and Neurological Devices

510(k) Number K040454